In a study of 57 patients previously treated with systemic chemotherapy for metastatic BRAF V600E-mutant NSCLC, the investigators showed an overall response of 63.2% (36 of 57, 95% CI: 49.3–75.6) with dabrafenib plus the MEK inhibitor trametinib67. Here, MAP2K7 is linked to non-small cell lung carcinoma.